Review Finds Cannabinoids Offer Modest Pain Relief, Best for Neuropathic Pain
A review of cannabinoid evidence found the strongest support for neuropathic pain and MS spasticity, with average pain reduction of only 0.5-1.0 points on a 10-point scale.
Quick Facts
What This Study Found
Evidence is strongest for neuropathic pain and MS-related spasticity, while results for fibromyalgia, osteoarthritis, and musculoskeletal pain remain inconsistent. Average pain reduction is modest (0.5-1.0 points on a 10-point scale). Discontinuation rates range from 4.3% at low-dose CBD to 12.9% at high-dose CBD vs. 3.5% on placebo. Nabiximols cause dizziness in 25% and somnolence in 8%.
Key Numbers
Pain reduction: 0.5-1.0 points on a 10-point scale. CBD discontinuation: 4.3% (low dose) to 12.9% (high dose) vs. 3.5% placebo. Nabiximols: 25% dizziness, 8% somnolence, 12% treatment discontinuation. High-dose CBD carries measurable hepatotoxicity risk.
How They Did This
Narrative review of clinical outcomes, adverse effects, and legal challenges of cannabinoids in chronic pain management, synthesizing evidence from multiple conditions and formulations.
Why This Research Matters
Despite growing interest in cannabinoids for pain, this review provides a sobering look at the actual magnitude of benefit: modest at best, with meaningful side effects and regulatory barriers.
The Bigger Picture
This review positions cannabinoids as adjunctive rather than first-line pain therapies, reserved for patients who do not respond to conventional treatment. The modest effect sizes and notable side effect profiles suggest cannabinoids are not the breakthrough pain solution some hope for.
What This Study Doesn't Tell Us
Narrative review without formal meta-analysis. Heterogeneous cannabinoid formulations, doses, and conditions make comparisons difficult. Regulatory differences across countries affect which data are available.
Questions This Raises
- ?Would standardized cannabinoid formulations produce more consistent results?
- ?For which specific pain conditions do cannabinoids outperform existing treatments?
Trust & Context
- Key Stat:
- Evidence Grade:
- Synthesizes multiple clinical trials and reviews with specific quantitative outcomes, though narrative format without systematic methodology limits to moderate.
- Study Age:
- Contemporary review of current cannabinoid pain evidence.
- Original Title:
- Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.
- Published In:
- Neurology international, 17(9) (2025)
- Authors:
- Sic, Aleksandar, George, Conor, Gonzalez, Daniela Ferrer, Tseriotis, Vasilis-Spyridon, Knezevic, Nebojsa Nick
- Database ID:
- RTHC-07654
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How much pain relief do cannabinoids actually provide?
On average, 0.5 to 1.0 points on a 10-point pain scale. This is statistically significant but clinically modest.
What are the main side effects?
The most common include dizziness (25% with nabiximols), drowsiness (8%), and dose-dependent discontinuation. High-dose CBD also carries hepatotoxicity risk.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-fibromyalgia-evidence-dosing
- cannabis-and-carpal-tunnel-nerve-pain
Cite This Study
https://rethinkthc.com/research/RTHC-07654APA
Sic, Aleksandar; George, Conor; Gonzalez, Daniela Ferrer; Tseriotis, Vasilis-Spyridon; Knezevic, Nebojsa Nick. (2025). Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.. Neurology international, 17(9). https://doi.org/10.3390/neurolint17090141
MLA
Sic, Aleksandar, et al. "Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.." Neurology international, 2025. https://doi.org/10.3390/neurolint17090141
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Eff..." RTHC-07654. Retrieved from https://rethinkthc.com/research/sic-2025-cannabinoids-in-chronic-pain
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.